Open Access

Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells

Contributed equally
Breast Cancer Research201719:5

https://doi.org/10.1186/s13058-017-0800-2

Received: 3 January 2017

Accepted: 3 January 2017

Published: 11 January 2017

The original article was published in Breast Cancer Research 2013 15:3254

Erratum

In the published article [1], the authors noticed an error to Fig. 1e in which the MTT curve of drug treatments (sorafenib, SC-1 and SC-43) in SK-BR3 cells was erroneously put as the same with that of HCC-1937 cells.

The correct version of Fig. 1 (including correct Fig. 1e) is included in this erratum.
Fig. 1

SC-1 and SC-43, without effects on raf-1 kinase activity, show more potent anti-proliferative activity than sorafenib in breast cancer cells. a chemical structures of sorafenib, SC-1 and SC-43. b effects of sorafenib, SC-1 and SC-43 on Raf-1 activity in MDA-MB-231 cells. Columns, mean (n = 3); bars, SD; *P <0.05 compared to control. c effects of sorafenib, SC-1 and SC-43 on the phosphorylation of ERK1/2, VEGFR2 and PDGFRβ in MDA-MB-231cells. Cells were exposed to sorafenib, SC-1 or SC-43 at 1 and 5 μM for 12 hours. Data are representative of three independent experiments. d effects of sorafenib, SC-1 and SC-43 on the phosphorylation of STAT3 upstream kinases JAK1 and JAK2 in MDA-MB-231 (Left) and MDA-MB-468 cells (Right). Cells were exposed to sorafenib, SC-1 or SC-43 at 1 and 5 μM for 12 hours. Data are representative of three independent experiments. e dose-escalation effects of sorafenib, SC-1 and SC-43 on cell viability in six breast cancer cell lines. Cells were exposed to sorafenib, SC-1 or SC-43 at the indicated doses for 48 hours and cell viability was assessed by the MTT assay. Points, mean (n = 3); bars, SD. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Institute of Biopharmaceutical Sciences, National Yang-Ming University
(2)
School of Medicine, National Yang-Ming University
(3)
Division of Hematology and Oncology, Taipei Veterans General Hospital
(4)
Department of Medicine, Taipei Veterans General Hospital
(5)
Department of Surgery, Taipei Veterans General Hospital
(6)
Department of Pathology, St. Martin De Porres Hospital
(7)
Department of Medical Research, National Taiwan University Hospital
(8)
National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital

Reference

  1. Liu CY, et al. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res. 2013;15:R63. doi:10.1186/bcr3457.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement